Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MarketBeat

Swarmer Q1 Earnings Call Highlights

Swarmer (NASDAQ:SWMR) reported a sharp year-over-year decline in first-quarter revenue in its first earnings call as a public company, while management emphasized that the company is investing in platform development, partnerships and international expansion as it seeks to position its autonomy soft

Alignment Healthcare Backs Q2 Outlook as Stable Costs, New Markets Lift Margin Hopes

Alignment Healthcare (NASDAQ:ALHC) executives said the company remains confident in its second-quarter outlook, citing stable medical cost trends, continued visibility into utilization and opportunities to expand margins as it grows outside California. Speaking at an analyst-led question-and-answer

Wix.com Q1 Earnings Call Highlights

Wix.com (NASDAQ:WIX) executives said the company delivered solid first-quarter 2026 growth while accelerating investments in artificial intelligence products, including Wix Harmony and Base44, during the company’s earnings call. President and Co-founder Nir Zohar said the company is focused on usin

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

WeRide Q1 Earnings Call Highlights

WeRide (NASDAQ:WRD) reported first-quarter 2026 revenue growth of 58% year over year, as management pointed to expanding Robotaxi deployments, broader autonomous driving commercialization and traction for its L2++ advanced driver assistance system. Founder, Chairman and CEO Dr. Tony Han said total

Valneva Q1 Earnings Call Highlights

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

D-Wave Earnings Looked Weak, But Investors May Be Missing This

D-Wave's long-awaited Q1 2026 earnings appear rough on the surface, with plunging revenue and widening losses, but many bright spots are hidden as well.

Nebius Upside Expands as AI Feedback Loop Intensifies

Nebius Group is growing at a hyper pace as hyperscalers lean into it for data center capacity and AI-related services.

inkl

Read news from The Economist, FT, and more,
with one subscription

Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell

Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell

See the recent insider activity surrounding Okta, Micron Technology, and Abbott Laboratories, and what these moves signal to investors.

Torm Q1 Earnings Call Highlights

Torm (NASDAQ:TRMD) reported a sharply stronger first quarter of 2026 and raised its full-year outlook, citing firm freight markets, geopolitical disruptions and what management described as the company’s operating advantages in a highly volatile tanker market. Chief Executive Officer Jacob Meldgaar

Sanuwave Health Q1 Earnings Call Highlights

Sanuwave Health (NASDAQ:SNWV) reported record first-quarter revenue and rising consumables utilization, while management said the advanced wound care market began to recover after a difficult start to the year tied to changes in reimbursement for skin substitutes. Chairman and CEO Morgan Frank said

Regis Q3 Earnings Call Highlights

Regis (NASDAQ:RGS) reported higher profitability and positive cash flow in its fiscal third quarter of 2026, even as total revenue declined, as the salon franchisor pointed to cost controls, company-owned salon improvements and a sharper focus on its largest brands under new Chief Executive Officer

PolyPid Q1 Earnings Call Highlights

PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery. Chief Executive Officer Di

PDS Biotechnology Q1 Earnings Call Highlights

PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs. On the company’s first quarter 2026 earnings call, Chief Executive Officer Dr. Frank

Nexxen International Q1 Earnings Call Highlights

Nexxen International (NASDAQ:NEXN) reported record first-quarter results for the three months ended March 31, 2026, and raised its full-year revenue outlook, citing stronger programmatic advertising demand, renewed growth in connected TV and early traction from its enterprise sales strategy. Chief

Get all your
news in one place.

100's of premium titles.
One news app.

Nebius Group Q1 Earnings Call Highlights

Nebius Group (NASDAQ:NBIS) reported a sharply higher first quarter for 2026 as demand for AI computing capacity continued to outpace supply, prompting management to raise its capital spending plans and expand its long-term power commitments. Co-founder and CEO Arkady Volozh said the company is buil

Milestone Pharmaceuticals Q1 Earnings Call Highlights

Milestone Pharmaceuticals (NASDAQ:MIST) said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibr

Plug Power Flips The Switch On Profitability

Plug Power's dramatic margin recovery and strategic execution are positioning it as a key leader in the hydrogen economy as it moves toward profitability.

3 Sectors That Look Most Vulnerable Ahead of May 15

A new Fed chair takes over May 15 as inflation stays elevated and three key market sectors flash bearish signals. Here's what investors need to watch.

Get all your
news in one place.

100's of premium titles.
One news app.

Qualcomm Stock Doubles: New Era? Or Another False Start?

Qualcomm’s hyperscaler win and AI ambitions may finally be offering the stock a new dawn, but investors have heard this story before.

Kamada Q1 Earnings Call Highlights

Kamada (NASDAQ:KMDA) reiterated its full-year 2026 outlook after reporting first-quarter results that management said were in line with expectations, excluding a temporary shipment delay that shifted revenue into April. Chief Executive Officer Amir London said demand across the company’s product po

Kornit Digital Q1 Earnings Call Highlights

Kornit Digital (NASDAQ:KRNT) reported first-quarter 2026 revenue at the high end of its guidance range and said customer activity is strengthening as the company pushes further into digital, on-demand textile production. Chief Executive Officer Ronen Samuel said on the company’s earnings call that

KLX Energy Services Q1 Earnings Call Highlights

KLX Energy Services (NASDAQ:KLXE) reported first-quarter 2026 revenue of $145 million and adjusted EBITDA of $11.1 million, with management describing the period as the likely low point for the fiscal year due to seasonal headwinds, weather disruptions and customer delays. President and Chief Execu

Gilat Satellite Networks Q1 Earnings Call Highlights

Gilat Satellite Networks (NASDAQ:GILT) reported a stronger first quarter of 2026, with management citing broad-based revenue growth, margin expansion and increased demand across defense, commercial satellite communications and Peru connectivity programs. Chief Executive Officer Adi Sfadia said the

Global-e Online Q1 Earnings Call Highlights

Global-e Online (NASDAQ:GLBE) reported stronger-than-expected first-quarter 2026 results and raised its full-year outlook, citing broad-based merchant growth, strong same-store sales and continued expansion of its cross-border e-commerce services. Co-founder and Chief Executive Officer Amir Schlach

Innate Pharma Q1 Earnings Call Highlights

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung

1 … 37 38 39 40

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

378,726 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play